Lv61
2720 积分 2023-03-05 加入
Lunsekimig's bispecific targeting of IL-13 and TSLP in asthma: dual targets for synergistic effects?
2小时前
已完结
BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR T-Cell Therapy
1天前
已完结
P3.18.38 Phase 3 eVOLVE-Lung02 Trial of Volrustomig + Chemotherapy (CT) vs Pembrolizumab + CT in Metastatic NSCLC With PD-L1 TC <50%
5天前
已关闭
OA13.02 Global Phase 2 Randomized Trial of BNT327 (Pumitamig; PD-L1 x VEGF-A bsAb) + Chemotherapy for 1L ES-SCLC: Dose Optimization Analysis
6天前
已关闭
Nanobody therapeutics in autoimmune and immune-mediated inflammatory diseases: experimental insights and translational strategies
9天前
已完结
Trends in the drug target landscape for autoimmune diseases
11天前
已完结
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China
1个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
1个月前
已完结
BCMA T-Cell Engager Therapy in Patients with Refractory Autoimmune Disease
1个月前
已完结
皖公网安备34019202002308
